Although computed tomography may change the criteria of cerebral angiography in neurosurgery, the neurosurgeon still requires angiographic confirmation of vascular anatomy at the operative sites, and catheterization for intra-luminal constructive surgery is also seeing progress. Cerebral angiography is a rather safe procedure; however, persistent serious neurological deficits and fatal complications are occasionally reported. The mechanisms of these complications are considered to be due to mechanically dislodged fragments of clots and/or atheroma, or direct endothelial damage by the catheter, contrast agents toxicity to brain tissue, anoxic neurocytologic injury due to the disturbance of the blood flow. Fluosol-DA (a type of perfluorochemical) has a potent oxygen-carrying capacity and has been safely used in humans as an artificial blood substitute. Meglumine diatrizoate (65% Angiografin) has not lost the x-ray opacification faculty in cerebral angiography by mixing with oxygenated Fluosol-DA, 20 up to 30 vol % of the latter in clinical use. In animal experiments, from 0.25 to 4 ml/kg of Angiografin-65 or Angiografin-65 with oxygenated Fluosol-DA, 20 were injected into the internal carotid artery of mongrel dogs. When 2.0 ml/kg of Angiografin-65 was injected into the carotid artery, remarkable arrhythmia was observed for 7.5 seconds. Blood pressure dropped 28.3 mmHg for 20.2 seconds; thereafter, it increased 25 mmHg in rebound for 15 seconds. Intracranial pressure increased 5 mmHg for 35 seconds, respiratory disturbance continued for 22.6 seconds. When a 20 vol % mixture of Fluosol-DA, 20 with Angiografin-65 was applied, these adverse reactions were markedly reduced.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source

Publication Analysis

Top Keywords

oxygenated fluosol-da
12
cerebral angiography
12
ml/kg angiografin-65
8
carotid artery
8
increased mmhg
8
fluosol-da
5
seconds
5
[contrast material
4
material oxygenated
4
fluosol-da protection
4

Similar Publications

Research into potential use of perfluorocarbons for liquid ventilation and as oxygen delivery agents in humans has been underway since the 1960s. While partial liquid ventilation with perfluorocarbons showed promise in animal models and early human investigation, randomized controlled human trials failed to show benefit and an elevated rate of adverse events. Initial approval of Fluosol-DA (Green Cross Corporation, Osaka, Japan) by the United States Food and Drug Administration as an oxygen delivery agent for use in high-risk coronary angioplasty represents the only approved application of these compounds to supplement tissue oxygenation, but the compound was rendered obsolete and removed from the market with the development of advanced angioplasty catheters in the 1990s.

View Article and Find Full Text PDF

Perfluorocarbon-based oxygen carriers: review of products and trials.

Artif Organs

August 2010

Blood Substitutes Laboratory, Fundación Cardio Infantil-Universidad de los Andes, Bogota, Colombia.

A viable blood substitute is still of great necessity throughout the world. Perfluorocarbon-based oxygen carriers (PFCOCs) are emulsions that take advantage of the high solubility of respiratory gases in perfluorocarbons (PFCs). Despite attractive characteristics, no PFCOC is currently approved for clinical uses.

View Article and Find Full Text PDF

Assessment of newly developed perfluorocarbon emulsion: oxygen carrying capacity as the blood substitute in vivo.

Artif Cells Blood Substit Immobil Biotechnol

September 2001

Division of Biophysics, Research Institute for Electronic Science, Hokkaido University, Sapporo, Japan.

This study provides the evaluation of oxygen carrying capacity of the novel perfluorocarbon emulsion (Neo-PFC) produced by the new emulsifying technology named High Pressure Process. For the performance comparison of oxygen carrying abilities of Neo-PFC and a representative PFC emulsion, the oxidation states of cerebral tissues in substituted animals were measured by near-infrared spectrometry. After the 70% exchange transfusion of whole blood of rats by Neo-PFC and Fluosol-DA, fractional inspired oxygen (FiO2) was gradually decreased from 100% to 0%.

View Article and Find Full Text PDF

Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions.

Br Med Bull

March 2000

Department of Anaesthesia and Intensive Care Medicine, University of Liège, Belgium.

The problems posed by transfusion of homologous blood have led to the development of substances able to replace the gas transporting properties of blood. Perfluorocarbons (PFCs) emulsions and modified haemoglobin (Hb) solutions have been developed for this goal and are now tested in clinical assays. PFCs are synthetic fluorinated hydrocarbons, capable of dissolving large quantities of oxygen (O2; without binding) at high inspired concentrations of O2, and of delivering this O2 to the tissues.

View Article and Find Full Text PDF

Objective: To review the current data on perfluorocarbon (PFC) emulsions and haemoglobin (Hb) solutions.

Data Sources: For this paper we analysed the literature using Medline search along with major review articles.

Data Selection And Extraction: The collected articles were reviewed and selected according to their quality and originality.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!